An Early Phase 1 interventional study of Lidocaine gel in ADHD and PMS, sponsored by PhenoSolve, LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by PhenoSolve, LLC · Early Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 309th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 48 in phase 1, and was the 548th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 32 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
PhenoSolve, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.
PhenoSolve, LLC has 3 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
Using a non-invasive, pain-free, taste-based approach to assess lidocaine effectiveness, the study will assess the frequency of ineffectiveness in the target population. We will use an identical protocol at two sites: Jacobi hospital and Boston Clinical Trials.
The controlled trial will assess the ability of lidocaine oral gel to block taste (e.g., sweet) in 100 teens and adults, half with a history of ADHD, and for females, we will compare the sub-groups with and without premenstrual syndrome (PMS).
This study will also be compared with a similar assessment among a specialized ADHD population (NCT03563573), that does not respond to existing medication..
Inclusion Criteria:
Exclusion Criteria for both arms:
(1) known adverse reactions to lidocaine; (2) ADHD, ADD, and other inattention disorders; (3) epilepsy, IQ \<80, severe head trauma, birth weight \<2270 grams, and severe autism; (4) treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers; (5) generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness); (6) mouth sores; (7) Ehlers Danlos syndrome, (8) red hair, and (9) current pregnancy.
All subjects get the lidocaine taste test
Drug: Lidocaine gel
Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
Also known as: Intervention
Number of Subjects With Lidocaine Ineffectiveness
Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 10 (very intense) scale before and after application of Lidocaine. Lidocaine effectiveness was quantitated as the reduction or elimination of taste by lidocaine compared to taste scores reported before lidocaine. For each of the four before/after pairs, the change in taste intensity was calculated, a weighted average score was computed. Incorrectly identified tastes were excluded. Scores of a reduction in taste ≥50% were considered to be lidocaine effective.
Time frame: 30 minute visit, added on to a regular clinic visit
| Milestone | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS |
|---|---|---|---|---|---|---|
| Started | 23 | 14 | 22 | 5 | 15 | 11 |
| Completed | 23 | 14 | 22 | 5 | 15 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 10 (very intense) scale before and after application of Lidocaine. Lidocaine effectiveness was quantitated as the reduction or elimination of taste by lidocaine compared to taste scores reported before lidocaine. For each of the four before/after pairs, the change in taste intensity was calculated, a weighted average score was computed. Incorrectly identified tastes were excluded. Scores of a reduction in taste ≥50% were considered to be lidocaine effective.
| Participants | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS |
|---|---|---|---|---|---|---|
| Lidocaine effective (gets numb) | 11 | 9 | 16 | 5 | 15 | 3 |
| Lidocaine ineffective (does not get numb) | 12 | 5 | 6 | 0 | 0 | 8 |
Collected over 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | 0/90 (0%) | 0/90 (0%) | 0/90 (0%) |
| Age, Categorical(Participants) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 14 | 22 | 5 | 15 | 11 | 90 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33 ± 7.6 | 27 ± 7.1 | 33 ± 6.4 | 33 ± 10.0 | 27 ± 6.1 | 30 ± 8.1 | 30 ± 7.5 |
| Sex: Female, Male(Participants) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 22 | 5 | 15 | 11 | 53 |
| Male | 23 | 14 | 0 | 0 | 0 | 0 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 6 | 2 | 4 | 4 | 24 |
| Not Hispanic or Latino | 18 | 11 | 16 | 3 | 11 | 7 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 2 | 1 | 1 | 0 | 2 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 2 | 7 | 1 | 2 | 2 | 22 |
| White | 7 | 8 | 10 | 4 | 9 | 6 | 44 |
| More than one race | 3 | 1 | 1 | 0 | 2 | 2 | 9 |
| Unknown or Not Reported | 3 | 2 | 2 | 0 | 0 | 1 | 8 |
| Region of Enrollment(Participants) | Males Without ADHD | Males With ADHD | Females Without ADHD and Without PMS | Females Without ADHD, But With PMS | Females With ADHD and Without PMS | Females With ADHD and With PMS | Total |
|---|---|---|---|---|---|---|---|
| United States | 23 | 14 | 22 | 5 | 15 | 11 | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We plan to submit for publication descriptions of what was accomplished, and the evaluations as described in the study, including the incidence of lidocaine ineffectiveness in those with ADHD and in the general population.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 9-12 months
Access criteria: Researchers
Data sharing details ↗ · phenosolve.com
Ran from Aug 2019 to primary completion in Mar 2020, 6 months.
Results were first posted in Jul 2021, 1 year 4 months after primary completion.
Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 6 months is above that.
Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Attention Deficit Disorder with Hyperactivity →
PhenoSolve, LLC